Valuation AstraZeneca PLC Buenos Aires S.E.

Stocks

End-of-day quote Buenos Aires S.E. 15/09/2026			5-day change	1st Jan Change
64,575.00 ^ARS	-1.22%		-0.54%	-8.47%

09-15	Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says	MT
09-15	AstraZeneca Chair Demare acquires 2,500 shares	AN

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	182,034	209,442	209,268	203,171	287,813	253,421	-	-
Change	-	15.06%	-0.08%	-2.91%	41.66%	-11.95%	-	-
Enterprise Value (EV) ¹	206,417	232,365	231,778	227,741	311,187	272,988	265,189	256,575
Change	-	12.57%	-0.25%	-1.74%	36.64%	-12.28%	-2.86%	-3.25%
P/E	1,469x	64.1x	35.4x	29.1x	28.4x	20.9x	18.2x	15.8x
PBR	4.24x	5.65x	5.39x	5.02x	5.96x	4.7x	4.17x	3.55x
PEG	-	0x	0.4x	1.6x	0.6x	1.1x	1.2x	1x
Capitalization / Revenue	4.87x	4.72x	4.57x	3.76x	4.9x	4.01x	3.79x	3.55x
EV / Revenue	5.52x	5.24x	5.06x	4.21x	5.3x	4.32x	3.97x	3.6x
EV / EBITDA	27.2x	25.2x	17.1x	13.6x	16x	12.3x	10.9x	9.59x
EV / EBIT	20.8x	17.4x	15.9x	13.5x	16.8x	13x	11.4x	10.1x
EV / FCF	42.4x	26.7x	25.8x	22.9x	26.5x	28.5x	20.4x	17.5x
FCF Yield	2.36%	3.75%	3.88%	4.36%	3.78%	3.51%	4.91%	5.7%
Dividend per Share ²	2.87	2.9	2.9	3.1	3.2	3.334	3.555	3.653
Rate of return	2.44%	2.15%	2.15%	2.37%	1.72%	2.04%	2.18%	2.24%
EPS ²	0.08	2.11	3.81	4.5	6.54	7.801	8.954	10.33
Distribution rate	3,588%	137%	76.1%	68.9%	48.9%	42.7%	39.7%	35.3%
Net sales ¹	37,417	44,351	45,811	54,073	58,739	63,260	66,874	71,305
EBITDA ¹	7,586	9,237	13,580	16,691	19,476	22,144	24,286	26,741
EBIT ¹	9,928	13,350	14,534	16,928	18,478	21,050	23,217	25,497
Net income ¹	112	3,288	5,961	7,035	10,225	12,057	13,801	15,814
Net Debt ¹	24,383	22,923	22,510	24,570	23,374	19,566	11,768	3,153
Reference price ²	117.51	135.16	135.02	131.05	185.60	163.39	163.39	163.39
Nbr of stocks (in thousands)	1,549,159	1,549,528	1,549,926	1,550,317	1,550,726	1,551,024	-	-
Announcement Date	10/02/22	09/02/23	08/02/24	06/02/25	10/02/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	32.41x	11.77x	23.88x	0.61%	1,015B
JOHNSON & JOHNSON	29.62x	6.59x	18.45x	2.02%	642B
ABBVIE INC.	33.52x	7.76x	16.03x	2.62%	463B
ROCHE HOLDING AG	19.65x	4.78x	11.85x	2.77%	353B
NOVARTIS AG	19.69x	5.14x	12.76x	3.13%	265B
ASTRAZENECA PLC	21.05x	4.32x	12.35x	2.04%	254B
AMGEN INC.	24.13x	6.36x	11.33x	2.64%	206B
NOVO NORDISK A/S	12.48x	4.54x	9.49x	4.03%	191B
GILEAD SCIENCES, INC.	-44.28x	6.46x	25.23x	2.25%	182B
Average	16.47x	6.41x	15.71x	2.46%	396.69B
Weighted average by Cap.	23.59x	7.64x	17.62x	2.01%